BIXT · Bioxytran, Inc
$0.02
0.00 (-4.27%)
At close · Sep 3
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.39M
Shares
114.70M
BIXT metrics
52 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.02
Market cap
$2.39M
Price action
19 metricsPrice change (1W)
-7.5%
Price change (30D)
-4.1%
Price change (3M)
-29.7%
Price change (6M)
-50.7%
Price change (YTD)
-72.2%
Price change (1Y)
-71.8%
Trailing year
Price change (5Y)
+4,120.0%
52-week high
$0.09
52-week low
$0.02
Change from 52-week high
-76.6%
Change from 52-week low
+1.4%
Annualized volatility
116.9%
Beta
-1.1
RSI (14D)
44.0
Price vs SMA 50
-13.7%
Price vs SMA 200
-52.4%
Avg volume (3M)
92,046
Relative volume
0.5
Average dollar volume
$2,211
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
114.70M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
13.5×
reciprocal yield 7.4%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-146.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
45.6%
Operating margin
-162.5%
Trailing 12 months
Net margin
-166.6%
Gross profit (TTM)
$83,521
Operating profit (TTM)
−$3.69M
Net income (TTM)
−$3.49M
Trailing 12 months
Diluted EPS (TTM)
$-0.03
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-48.5%
Year over year
Net income growth YoY
-1,849.3%
Revenue (TTM)
$177,794
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+28.7%
Year over year · more shares
Revenue CAGR (3Y)
-11.5%
Revenue CAGR (5Y)
-9.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-1,048.0%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
-25.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$23,448
Total assets
$333,393
Total debt
$48,070
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$874,319
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$193,089
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
7 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged